BOC Sciences, a leading chemical supplier has lately announced the launch of cell apoptosis assay services for scientists engaged in drug recovery research. BOC Sciences, a New York based supplier of various bio-chemicals has been dedicated to the pharmaceutical industry by supplying a wide range of products to researchers such as GMP products, ADC’s and various biochemicals such as inhibitors, API’s, metabolites and impurities. The supplier also gets involved with drug discovery by enabling a wide range of services through all stages of drug R&D like the custom synthesis of chemicals, isotope labeling, formulation service, antibody-drug conjugates and chiral synthesis. With expertise and cell assays, the researchers now need not worry about the detection of apoptosis anymore.
Apoptosis also referred to as programmed cell death plays a significant role in several human diseases is controlled by multiple signaling and effector pathways. Apoptosis has been found to be closely linked with caspase related apoptotic enzyme cascades, mitochondrial depolarization, DNA fragmentation and cell blebbing & destruction. Scientists have claimed that through approaches of genetically modulating these apoptosis-associated pathways, new therapies might be discovered.
Professor Jones, a senior scientist from BOC Sciences has stated that several human conditions like neurodegenerative diseases or autoimmune disorders are caused by inappropriate death of the cells and thus it is very useful to precisely detect and measure apoptosis in order to understand the cell death mechanisms. A lot of efforts have been taken to unveil apoptosis mechanisms with the expectation to use new strategies based on the potential therapeutic benefit of apoptosis.
There are two factors that account for the significance and the prevalence of cell apoptosis assay in drug R&D. The first factor being that cell death is widely involved in various processes like cell turnover, functioning of the immune system and embryonic development. The second factor being that the fine balance between cell survival and death is regulated by varieties of cellular proteins such as receptors and adaptors thereby causing the mutations of these sensors or effector proteins to tip the balance and finally result in the uncontrolled survival and rise of cancer cells.
On the other hand, the assay development has become a critical part for hit discovery in spite of the fact that pharmaceutical companies approach drug discovery in many ways and luckily, by using high-throughput screening(HTS) and based on improved cell death assays, the discovery of disease-modifying therapeutics has been made possible for the treatment of neurodegenerative diseases. Neurodegenerative diseases cannot usually be slowed down by any current therapies.
According to a report published by Value Market Research, the rise in the count of the population suffering from cancer, autoimmune diseases and neurodegenerative diseases is driving the demand for market growth. Also, the increase in the expenditure by the government on cancer research and the rising demand for high content screening and drug development especially for cancer is again responsible for boosting the market growth.
With experience in chemical molecules, cell lines culturing, apoptotic biology and flow cytometry technologies application, the scientists at BOC are capable of providing apoptotic services, including systemic experimental design, operation and data analysis as well as the selection of the most appropriate detection assays. The apoptotic services that are going to be provided by the scientists at BOC Sciences are MTT assay & flow cytometry apoptotic detection assay, caspase activity detection, membrane change detection and cell morphology detection.
Naira Shekhawat has been into Content Writing just after completing her Graduation in English Literature. Her love for words has won her many accolades in her respective jobs ever since. Naira covers business sections for VMR News. She is a traveller by heart and loves writing on food blogs as a freelancer.